Sansure Biotech(SH:688289) Shang Hai Zheng Quan Bao·2025-11-28 19:21Core Viewpoint - The company has adjusted the grant price of the 2023 second phase restricted stock incentive plan from 8.55 yuan per share to 8.01 yuan per share, aligning the grant price of the reserved portion with the initial grant price [1][8][26]. Group 1: Decision-Making Process and Disclosure - The company held a board meeting on November 30, 2023, to approve the incentive plan and related proposals, with independent directors providing their opinions [2][14]. - The company disclosed the collection of proxy voting rights from shareholders for the upcoming general meeting on December 2, 2023 [3]. - The names and positions of the incentive plan participants were publicly announced from December 3 to December 12, 2023, with no objections received [4][15]. Group 2: Adjustment Reasons and Results - The adjustment in the grant price was necessitated by the company's capital distribution actions, including cash dividends of 2.75 yuan and 2.62 yuan per 10 shares, which required a corresponding adjustment to the grant price [6][8]. - The adjusted grant price calculation resulted in a new price of 8.01 yuan per share, ensuring it remains above the par value of the company's stock [8][9]. Group 3: Impact of the Adjustment - The adjustment of the grant price does not have a substantial impact on the company's financial status or operational results [9][19]. Group 4: Committee Opinions - The Compensation and Assessment Committee confirmed that the adjustment of the grant price was appropriate and complied with relevant regulations, ensuring no harm to the interests of the company and its shareholders [11][21]. Group 5: Legal Opinions - The legal opinion from Hunan Qiyuan Law Firm confirmed that the adjustments and actions taken regarding the incentive plan have received necessary approvals and comply with applicable laws and regulations [12][22].